Study on evaluation criteria for the quality of Chinese patent medicine purchased centrally by the Guangdong alliance
- VernacularTitle:广东联盟中成药集采品种质量评价标准研究
- Author:
Juliang CHEN
1
,
2
;
Hui ZHANG
1
,
2
;
Huiyun LIN
1
,
2
;
Ziwei HU
1
Author Information
1. Dept. of Pharmacy，the Second Affiliated Hospital of Guangzhou University of Chinese Medicine/Guangdong Provincial Hospital of Chinese Medicine，Guangzhou 510120，China
2. Dept. of Pharmacy，Zhuhai Hospital，Guangdong Provincial Hospital of Chinese Medicine，Guangdong Zhuhai 519000，China
- Publication Type:Journal Article
- Keywords:
Chinese patent medicine;
centralized procurement;
quality evaluation;
quality control;
therapeutic effect
- From:
China Pharmacy
2023;34(17):2057-2062
- CountryChina
- Language:Chinese
-
Abstract:
Since the Guangdong alliance launched the centralized procurement of Chinese patent medicine， manufacturers have engaged in fierce price competition to obtain the qualification for selection. In order to ensure that manufacturers have lowered the price without decreasing quality， the evaluation criteria for the quality of Chinese patent medicine is constructed on the basis of the characteristics of traditional Chinese medicine. The evaluation criteria consist of the production process and therapeutic effect evaluation. The evaluation indicators involve raw materials， processing and clinical use covering the whole life cycle of Chinese patent medicine. The evaluation of production process includes 3 secondary indicators （the quality of traditional Chinese medicine， the quality of traditional Chinese medicine decoction pieces and the quality of Chinese patent medicines） and 13 tertiary indicators （standardized production， quality inspection， processing specifications， technical processes， safety risk control， etc.）， which fully reflect the quality control of key links in the production of Chinese patent medicine. The therapeutic effect evaluation includes 5 secondary indicators （theoretical origin of formulation， proactive research by production enterprises， evidence-based medical evidence， clinical use， and technological embodiment） and 18 tertiary indicators （theoretical sources， post-market effectiveness re- evaluation， clinical guidelines， expert consensus， etc.） to assess the quality and efficacy of Chinese patent medicine from multiple perspectives and levels. This study is a useful supplement to the scheme of centralized procurement of Guangdong alliance， which can not only provide data support for selecting “low-cost and high-quality” Chinese patent medicine， but also provide information reference for hospitals to make procurement decisions.
